高级检索
当前位置: 首页 > 详情页

Nucleophosmin promotes lung adenocarcinoma cell proliferation, migration and invasion by activating the EGFR/MAPK signaling pathway

| 导出 | |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Kunming Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, 295 Xichang Rd, Kunming 650032, Yunnan, Peoples R China [2]Kunming Univ Sci & Technol, Peoples Hosp Yunnan Prov 1, Affiliated Hosp, Dept Radiol, Kunming 650034, Yunnan, Peoples R China
出处:
ISSN:

关键词: lung adenocarcinoma nucleophosmin EGFR MAPK signaling pathway tumorigenesis prognosis

摘要:
Lung adenocarcinoma (LUAD) is the main cause of death globally. The present study investigated the prognostic value and functional verification of nucleophosmin (NPM1) in LUAD. LUAD and normal samples from The Cancer Genome Atlas were analyzed to identify whether NPM1 is associated with LUAD prognosis. NPM1 protein expression level was verified by western blotting. Cell proliferation, migration and invasion were detected by Cell Counting Kit-8, wound healing and Transwell assays, respectively. EGFR/MAPK pathway-related proteins [phosphorylated (p)-EGFR/EGFR, p-MEK/MEK, and p-ERK/ERK] expression was measured through western blotting. A xenograft tumor mice model was constructed to perform the in vivo verification. NPM1 was upregulated in LUAD cells, and high-level NPM1 indicated poor prognosis in patients with LUAD. In vitro experiments revealed that NPM1 knockdown inhibited LUAD cell proliferation, migration and invasion. Moreover, protein expression of p-EGFR/EGFR, p-MEK/MEK and p-ERK/ERK was reduced with the NPM1 silencing. Furthermore, EGF, an activator of the EGFR/MAPK pathway, reversed the effects of NPM1. In vivo experiments showed that NPM1 knockdown inhibited tumor growth and protein levels of p-EGFR/EGFR, p-MEK/MEK and p-ERK/ERK. NPM1 is related to the poor prognosis of LUAD and promotes the malignant progression of LUAD by activating the EGFR/MAPK pathway. This discovery provides a new potential therapeutic target for the diagnosis and treatment of LUAD.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2024]版:
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2023]版:
Q2 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Kunming Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, 295 Xichang Rd, Kunming 650032, Yunnan, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Kunming Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, 295 Xichang Rd, Kunming 650032, Yunnan, Peoples R China [*1]Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, Yunnan 650032, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:53661 今日访问量:0 总访问量:1665 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)